1. Abe, J., Nakano, T., Nishii, Y., Matsumoto, T., Ogata, E., and Ikeda, K., 1991, A novel vitamin D3 analog, 22-oxa-1,25 dihydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia, Endocrinology 129:832–837.
2. Abe-Hashimoto, J., Kikuchi, T., Matsumoto, T., Nishii, Y., Ogata, E., and Ikeda, K., 1993, Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen, Cancer Res. 53:2534–2537.
3. Anzano, M. A., Smith, J. M., Uskokovic, M. R., Peer, C. W., Mullen, L. T., Letterio, J. J., Welsh, M. C., Shrader, M. W., Logsdon, D. L., Driver, C. L., Brown, C. C., Roberts, A., and Sporn, M. B., 1994, 1α,25-Dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat, Cancer Res. 54:1653–1656.
4. Barry, M. A., Behnke, C. A., and Eastman, A., 1990, Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia, Biochem. Pharmacol 40:2353–2362.
5. Battcharjee, M., Weintroub, S., and Vonderhaar, B. K., 1987, Milk protein synthesis of vitamin D deficient mice, Endocrinology 121:865–874.